Tian Zhang, MD | Authors


A Phase III Trial of Pembrolizumab as Adjuvant Treatment for Renal Cell Carcinoma

February 26, 2018

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the phase III KEYNOTE-564 trial of pembrolizumab (Keytruda) as adjuvant treatment for renal cell carcinoma (RCC).